A carregar...
Neoadjuvant sipuleucel-T induces both Th1 activation and immune regulation in localized prostate cancer
Sipuleucel-T is the only FDA-approved immunotherapy for metastatic castration-resistant prostate cancer. The mechanism by which this treatment improves survival is not fully understood. We have previously shown that this treatment can induce the recruitment of CD4 and CD8 T cells to the tumor microe...
Na minha lista:
| Publicado no: | Oncoimmunology |
|---|---|
| Main Authors: | , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Taylor & Francis
2018
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6287789/ https://ncbi.nlm.nih.gov/pubmed/30546940 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2018.1486953 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|